Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | DAO | P14920 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 3/20 | 0.37 |
| ▸ | RXRG | P48443 | 3/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | RARG | P13631 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810308 | 0.84 | HCAR2 (0.61) | HCAR2ALDH1A1DAOKDM4EGAA | |
| SCHEMBL24036436 | 0.83 | HCAR2 (0.57) | HCAR2ALDH1A1DAOKDM4EGAA | |
| SCHEMBL17204603 | 0.83 | HCAR2 (0.50) | HCAR2ALDH1A1DAOKDM4EGAA | |
| Hydrochloric Acid SCHEMBL11597191 | 0.82 | HCAR2 (0.59) | HCAR2ALDH1A1DAOKDM4EGAA | |
| SCHEMBL21836283 | 0.82 | ALDH1A1 (0.42) | HCAR2ALDH1A1KDM4EGAARAB9A | |
| SCHEMBL4019091 | 0.78 | HCAR2 (0.55) | HCAR2ALDH1A1DAOKDM4EGAA | |
| SCHEMBL324369 | 0.77 | — | — | |
| SCHEMBL186167 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL29229113 | 0.76 | HCAR2 (0.57) | HCAR2ALDH1A1DAOKDM4EGAA | |
| SCHEMBL1357514 | 0.75 | ALDH1A1 (0.46) | HCAR2ALDH1A1KDM4ERAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567388-B | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117567388-A | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-117567388-B | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117567388-B | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117567388-B | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117567388-A | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117567388-A | Synthesis method of 2-acetyl-5-thiazole formic acid | 济南悟通生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HCAR2 4010/4885ALDH1A1 2691/4885DAO 3162/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | HCAR2 3810/4885ALDH1A1 1036/4885DAO 306/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | HCAR2 2921/4885ALDH1A1 2165/4885DAO 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.